EGFR and head and neck squamous cell carcinoma: The role of epidermal growth factor receptor (EGFR) for therapy resistance of HNSCC has been an active field of investigation, since EGFR inhibitor cetuximab was introduced and approved for use in HNSCC [11, 12].